New drugs for atrial fibrillation

被引：0
作者：
Matthias Hammwöhner
Jan Smid
Uwe Lendeckel
Andreas Goette
机构：
[1] University Hospital Magdeburg,Division of Cardiology
[2] University Hospital Magdeburg,Institute of Experimental Internal Medicine
来源：
Journal of Interventional Cardiac Electrophysiology | 2008年 / 23卷
关键词：
Atrial fibrillation; Therapy; Drugs; Pathophysiology; Pharmacology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Epidemiologic studies suggest that the number of patients with AF will triple in the next 30 years, and therefore, its impact on medical and economic issues will further increase. Due to the limited efficacy and significant side effects of antiarrhythmic drugs, much effort has been made to develop alternative pharmacologic treatments for AF. Novel approaches include new antiarrhythmic drugs and novel drug targets involved in molecular, proarrhythmogenic, atrial remodeling. Furthermore, novel anticoagulants are now clinically studied. This review briefly summarizes new developments in the pharmacotherapy for AF.
引用
收藏
页码：15 / 21
页数：6
相关论文
共 222 条
[1]  
Fuster V.(2006)ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 1
[2]  
Ryden L. E.(1982)Epidemiologic features of chronic atrial fibrillation: The Framingham study New England Journal of Medicine 306 1018-1022
[3]  
Cannom D. S.(2006)[New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers] Herzschrittmachertherapie & Elektrophysiologie 17 64-72
[4]  
Crijns H. J.(2002)Cellular electrophysiology of atrial fibrillation Cardiovascular Research 54 259-269
[5]  
Curtis A. B.(2006)AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat Circulation 114 1234-1242
[6]  
Ellenbogen K. A.(2007)Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovascular Research 75 89-98
[7]  
Kannel W. B.(2006)Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: A comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit Europace 8 549-557
[8]  
Abbott R. D.(2004)Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model Journal of Cardiovascular Electrophysiology 15 1444-1450
[9]  
Savage D. D.(2004)Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels Naunyn-Schmiedeberg’s Archives of Pharmacology 370 183-192
[10]  
McNamara P. M.(2007) and Journal of Cardiovascular Pharmacology 49 197-206
12345678910